quantisnow
FeedTopReportsPricing
⌘K
Live feed
18:00:00·2d
PRRelease
Nuvation Bio Inc. logo

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

NUVB· Nuvation Bio Inc.
Health Care
Original source

Companies

  • NUVB
    Nuvation Bio Inc.
    Health Care

Recent analyst ratings

  • Nov 24UpdateTruist-
  • Nov 19UpdateB. Riley Securities$12.00
  • Sep 30UpdateJefferies$10.00
  • Apr 23UpdateCitizens JMP$6.00
  • Mar 27UpdateJefferies$10.00
  • Mar 26UpdateBTIG Research$5.00

Related

  • PR2d
    /U P D A T E -- Nuvation Bio Inc./
  • INSIDER2d
    SEC Form 4 filed by Wentworth Kerry
  • INSIDER2d
    SEC Form 4 filed by Liu Dongfang
  • SEC2d
    SEC Form DEFA14A filed by Nuvation Bio Inc.
  • PR3d
    Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
  • SEC6d
    SEC Form 144 filed by Nuvation Bio Inc.
  • SEC13d
    SEC Form DEF 14A filed by Nuvation Bio Inc.
  • INSIDER15d
    SEC Form 4 filed by Wentworth Kerry
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022